Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | HTR1B | P28222 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR7 | P34969 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | HTR2B | P41595 | 1/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.95 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.95 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.54 |
| ▸ | SCN4A | P35499 | 4/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL22165339 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28361114 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL3947282 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28345162 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL2048695 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL153875 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Dexpramipexole SCHEMBL2289178 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28506481 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Dexpramipexole SCHEMBL910147 | 0.99 | ADRA2A (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL20524815 | 0.99 | DRD3 (0.97) | DRD3DRD2DRD4ADRA2AHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022131880-A2 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | 코스맥스파마 주식회사 | 2022-06-23 | — | — | WO | claimed |
| CN-112724102-A | Pramipexole related compound and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2021-04-30 | — | — | CN | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3777858-B1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES (JP) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024187537-A1 | PRAMIPEXOLE XINAFOATE SUSTAINED-RELEASE MICROSPHERE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东泰合医药科技有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| CN-111902143-B | Inhibitors of calcium concentration increase in nerve cells | 东丽株式会社 | 2024-01-02 | — | — | CN | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-115884788-A | Kinases as biomarkers for neurodegenerative conditions | 才思治疗公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023282283-A1 | COMPOSITION FOR IMPROVING ORAL ENVIRONMENT | 明治ホールディングス株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | TORAY INDUSTRIES, INC. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20090246186-A1 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | KANEKA CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2005951-A9 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | Kaneka Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090130197-A1 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT | FRIEDL THOMAS | 2009-05-21 | — | — | US | disclosed |
| EP-2005951-A2 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | Kaneka Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| CN-101022788-A | Extended release pellet formulations comprising pramipexole or a pharmaceutically acceptable salt thereof, methods of preparation and uses thereof | BOEHRINGER INGELHEIM INT (DE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1787657-A1 | THERAPEUTIC AGENT FOR PSYCHONEUROTIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
| EP-1778201-A2 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | Boehringer Ingelheim International GmbH (DE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060051419-A1 | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| WO-2006015943-A2 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | ITPR2, ATP2A2, ORAI1 | DRD3 2981/4885DRD2 2065/4885DRD4 3360/4885 |
| US-20060051419-A1 | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | CRH, MC2R, MME | DRD3 1413/4885DRD2 1037/4885DRD4 661/4885 |
| US-20090130197-A1 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT | CRH, MC2R, LPXN | DRD3 1349/4885DRD2 1008/4885DRD4 705/4885 |
| US-20090246186-A1 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | NLN, BDNF, ACHE | DRD3 3834/4885DRD2 3782/4885DRD4 3376/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | DRD3 59/4885DRD2 58/4885DRD4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.